Abstract 14P
Background
Host tumor microenvironment (TME) assessment is considered to play an important role in the prognostic and therapeutic predictions of breast cancer treatment. No consensus has been reached regarding evaluation methods despite reports of the utilization of tumor-infiltrating lymphocytes (TILs) for tumor immune microenvironment (TIME) monitoring. While the International Working Group recommends a tumor stromal evaluation, the timing of TIME assessment has not yet been established. Here, we focused on the assessment time and verified clinical predictions of neoadjuvant chemotherapy (NAC) effects using TILs.
Methods
Two hundred thirty-nine patients were treated with neoadjuvant chemotherapy (NAC). During the period from diagnostic needle biopsy to NAC initiation for breast cancer, the optimal evaluation timing was examined using a receiver operating characteristic (ROC) curve analysis.
Results
The prognostic analysis revealed that both disease-free survival (DFS) and overall survival (OS) were significantly prolonged in the short-term group (118 patients) relative to the long-term group (121 patients) (p = 0.020, p = 0.010, log-rank). A significant correlation between TILs and pathological complete response (pCR) was only observed in the short-term group (p = 0.033). Prognostic analysis revealed that in the short-term group, the high TIL group had a significantly better survival prognosis relative to the low TIL group (DFS: p = 0.001, OS: p = 0.021, log-rank). TILs were also found to be a significant factor affecting DFS in the univariate analysis (p = 0.004, hazard ratio = 0.115), as well as an independent factor affecting the DFS in a multivariate analysis (p = 0.008, hazard ratio = 0.130).
Conclusions
The timing of TIL assessment during NAC for breast cancer may be more sensitive index in the short term (≤35 days).
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
42P - Genome wide copy number analysis of circulating tumour cells in breast cancer liver metastasis
Presenter: Saber Imani
Session: Poster display session
Resources:
Abstract
43P - A hotspot variants p.H1047R and p.H1047L in p110α/ΔNp63α complex affects structure, function and contributes to susceptibility metastatic breast cancer
Presenter: Zou Linglin
Session: Poster display session
Resources:
Abstract
44P - Correlation of circulating tumour cells with PET-CT in metastatic breast cancer
Presenter: Venkata Pradeep Babu Koyyala
Session: Poster display session
Resources:
Abstract
45P - The challenge of evaluating new targeted therapies: Opportunities in stratifying the therapeutic response per tumour location
Presenter: Hubert Beaumont
Session: Poster display session
Resources:
Abstract
46P - Plasma soluble CD36 of breast cancer based on pathological and clinical characteristics
Presenter: Aditia Romadhoni
Session: Poster display session
Resources:
Abstract
47P - Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer
Presenter: MAYUKO MIKI
Session: Poster display session
Resources:
Abstract
48P - Development of MDA-MB-231-3D-Spheroid as a reliable model for studying Nav1.5 and nNav1.5-mediated breast cancer metastasis
Presenter: Ahmad Murtadha
Session: Poster display session
Resources:
Abstract
49P - Biochemical study on modifying role of variants of leptin gene and its receptor on serum leptin levels in breast cancer
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
50P - Prognostic factors of recurrence or distant metastasis in elderly breast cancer patients
Presenter: Seungju Lee
Session: Poster display session
Resources:
Abstract
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract